Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition

Abstract The Hand, Foot and Mouth Disease (HFMD) is a highly contagious viral illness generally manifests as a mild disease in young children and immunocompromised adults. It has however emerged as a significant public health threat in recent years as outbreaks have been occurring regularly, especia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Wah Tan, Wan Keat Yam, Rachel Jia Wen Kooi, Jacob Westman, Gustav Arbrandt, Justin Jang Hann Chu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6a2b28ceaf404012bffe441f95c15b18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a2b28ceaf404012bffe441f95c15b18
record_format	dspace
spelling	oai:doaj.org-article:6a2b28ceaf404012bffe441f95c15b182021-12-02T16:51:49ZNovel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition10.1038/s41598-021-89271-82045-2322https://doaj.org/article/6a2b28ceaf404012bffe441f95c15b182021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89271-8https://doaj.org/toc/2045-2322Abstract The Hand, Foot and Mouth Disease (HFMD) is a highly contagious viral illness generally manifests as a mild disease in young children and immunocompromised adults. It has however emerged as a significant public health threat in recent years as outbreaks have been occurring regularly, especially in the Asia–Pacific. The disease can result from infections by a wide variety of human enteroviruses, particularly, Enterovirus A71 (EV-A71) has garnered more attention due to its association with severe disease in infected patients. Despite the potential to result severe neurological complications or even fatality, there is currently no effective antiviral for treatment of EV-A71 infections and the only vaccines available are restricted to distribution in China. In this study, we report the in vitro and in vivo evaluation of two candidate antiviral compounds active against EV-A71, a viral capsid inhibitor (G197) and a novel host-targeting phosphatidylinositol 4-kinase III beta inhibitor (N373) which, especially when used in combination, can significantly improve the survival and pathology of infected mice.Yong Wah TanWan Keat YamRachel Jia Wen KooiJacob WestmanGustav ArbrandtJustin Jang Hann ChuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yong Wah Tan Wan Keat Yam Rachel Jia Wen Kooi Jacob Westman Gustav Arbrandt Justin Jang Hann Chu Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
description	Abstract The Hand, Foot and Mouth Disease (HFMD) is a highly contagious viral illness generally manifests as a mild disease in young children and immunocompromised adults. It has however emerged as a significant public health threat in recent years as outbreaks have been occurring regularly, especially in the Asia–Pacific. The disease can result from infections by a wide variety of human enteroviruses, particularly, Enterovirus A71 (EV-A71) has garnered more attention due to its association with severe disease in infected patients. Despite the potential to result severe neurological complications or even fatality, there is currently no effective antiviral for treatment of EV-A71 infections and the only vaccines available are restricted to distribution in China. In this study, we report the in vitro and in vivo evaluation of two candidate antiviral compounds active against EV-A71, a viral capsid inhibitor (G197) and a novel host-targeting phosphatidylinositol 4-kinase III beta inhibitor (N373) which, especially when used in combination, can significantly improve the survival and pathology of infected mice.
format	article
author	Yong Wah Tan Wan Keat Yam Rachel Jia Wen Kooi Jacob Westman Gustav Arbrandt Justin Jang Hann Chu
author_facet	Yong Wah Tan Wan Keat Yam Rachel Jia Wen Kooi Jacob Westman Gustav Arbrandt Justin Jang Hann Chu
author_sort	Yong Wah Tan
title	Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
title_short	Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
title_full	Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
title_fullStr	Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
title_full_unstemmed	Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
title_sort	novel capsid binder and pi4kiiibeta inhibitors for ev-a71 replication inhibition
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6a2b28ceaf404012bffe441f95c15b18
work_keys_str_mv	AT yongwahtan novelcapsidbinderandpi4kiiibetainhibitorsforeva71replicationinhibition AT wankeatyam novelcapsidbinderandpi4kiiibetainhibitorsforeva71replicationinhibition AT racheljiawenkooi novelcapsidbinderandpi4kiiibetainhibitorsforeva71replicationinhibition AT jacobwestman novelcapsidbinderandpi4kiiibetainhibitorsforeva71replicationinhibition AT gustavarbrandt novelcapsidbinderandpi4kiiibetainhibitorsforeva71replicationinhibition AT justinjanghannchu novelcapsidbinderandpi4kiiibetainhibitorsforeva71replicationinhibition
_version_	1718382922721918976

Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition

Ejemplares similares